| Serial Number | 97251361 |
| Word Mark | CELLIPONT BIOSERVICES |
| Filing Date | Thursday, February 3, 2022 |
| Status | 819 - SU - REGISTRATION REVIEW COMPLETE |
| Status Date | Thursday, March 28, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 4, 2023 |
| Goods and Services | Manufacturing services for others in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals, namely, custom manufacture of pharmaceuticals, chemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing services for others in the fields of mammalian cell banks, plasmids, purified mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians, namely, custom manufacture of pharmaceuticals, chemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing process consulting; Production in the nature of custom manufacture of cell lines for others using lentivirus technology; Production in the nature of custom manufacture of a recombinant or manipulated lentivirus; Production in the nature of custom manufacture of mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians |
| Goods and Services | Providing regulatory compliance and regulatory compliance consultation and advisory services with respect to relevant state and federal law for organizations in the pharmaceutical, biotech, life science, and other government-regulated industries |
| Disclaimer with Predetermined Text | "BIOSERVICES" |
| Goods and Services | Research and development in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, research and development in the fields of assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services, namely, research and development in the fields of assaying, and purifying mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; CDMO (Contract Development and Manufacturing Organization) services, namely, pharmaceutical drug development services; material testing; product quality testing; scientific laboratory services; scientific research |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 8, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | Monday, February 14, 2022 |
| First Use In Commerce Date | Monday, February 14, 2022 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 8, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, February 14, 2022 |
| First Use In Commerce Date | Monday, February 14, 2022 |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 8, 2022 |
| Primary Code | 045 |
| First Use Anywhere Date | Monday, February 14, 2022 |
| First Use In Commerce Date | Monday, February 14, 2022 |
| Party Name | Performance Cell Manufacturing, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Poway, CA 92064 |
| Party Name | Performance Cell Manufacturing, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Poway, CA 92064 |
| Event Date | Event Description |
| Friday, March 29, 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Thursday, March 28, 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Monday, March 4, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| Monday, February 12, 2024 | USE AMENDMENT FILED |
| Monday, March 4, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Monday, February 12, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, August 29, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 4, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 4, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 14, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, June 1, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, May 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, May 24, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, May 24, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, November 28, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, November 28, 2022 | NON-FINAL ACTION E-MAILED |
| Monday, November 28, 2022 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 16, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, February 8, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, February 7, 2022 | NEW APPLICATION ENTERED |